Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP8 | P40818 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | USP5 | P45974 | 1/20 | 0.37 |
| ▸ | USP4 | Q13107 | 1/20 | 0.37 |
| ▸ | USP7 | Q93009 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | KHK | P50053 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9356027 | 0.91 | USP8 (0.41) | USP8USP2USP5USP4USP7 | |
| SCHEMBL507982 | 0.90 | USP8 (0.44) | USP8USP2USP5USP4USP7 | |
| SCHEMBL10993243 | 0.87 | USP8 (0.37) | USP8USP2USP5USP4USP7 | |
| SCHEMBL20036425 | 0.82 | USP8 (0.40) | USP8USP2USP5USP4USP7 | |
| SCHEMBL12682521 | 0.82 | PLAU (0.38) | USP8USP2USP5USP4USP7 | |
| SCHEMBL3607648 | 0.82 | KDM4E (0.44) | USP8USP2USP5USP4USP7 | |
| Water SCHEMBL11498438 | 0.82 | USP8 (0.37) | USP8USP2USP5USP4USP7 | |
| SCHEMBL8200210 | 0.82 | ALDH1A1 (0.45) | USP8KDM4EALDH1A1CSNK1A1CLK4 | |
| SCHEMBL24263905 | 0.80 | USP8 (0.39) | USP8KDM4EALDH1A1CSNK1A1CLK4 | |
| SCHEMBL19484668 | 0.80 | USP8 (0.39) | USP8KDM4EALDH1A1CSNK1A1CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12303570-B2 | Compositions and methods for assessing eye vasculature | MEDIBEACON INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-20230132384-A9 | COMPOSITIONS AND METHODS FOR ASSESSING EYE VASCULATURE | MEDIBEACON INC. | 2023-04-27 | — | — | US | disclosed |
| EP-3882236-B1 | PRODUCTION METHOD FOR 2,5-DICYANO-3,6-DIHALOGENOPYRAZINE | UNIV KYUSHU NAT UNIV CORP (JP) | 2023-01-11 | — | — | EP | disclosed |
| EP-3882243-B1 | DICYANOPYRAZINE COMPOUND, LUMINESCENT MATERIAL AND LIGHT TRANSMITTER USING SAME | UNIV KYUSHU NAT UNIV CORP (JP) | 2023-01-04 | — | — | EP | disclosed |
| EP-3375779-B1 | 2,3-DICYANOPYRAZINE COMPOUND, LUMINESCENT MATERIAL AND LIGHT TRANSMITTER USING THE SAME | UNIV KYUSHU NAT UNIV CORP (JP) | 2022-09-07 | — | — | EP | disclosed |
| US-20220127237-A1 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | MEDIBEACON INC. | 2022-04-28 | — | — | US | disclosed |
| CN-108137554-B | Dicyanopyrazine compound, light-emitting material, light-emitting element using the light-emitting material, and method for producing 2, 5-dicyano-3, 6-dihalopyrazine | 国立大学法人九州大学 | 2022-03-18 | — | — | CN | disclosed |
| US-20220016269-A1 | COMPOSITIONS AND METHODS FOR ASSESSING EYE VASCULATURE | MEDIBEACON INC (US) | 2022-01-20 | — | — | US | disclosed |
| US-11160880-B2 | Compositions and methods for assessing eye vasculature | MEDIBEACON INC. (US) | 2021-11-02 | — | — | US | disclosed |
| EP-3882236-A1 | PRODUCTION METHOD FOR 2,5-DICYANO-3,6-DIHALOGENOPYRAZINE | Kyushu University National University Corporation (JP) | 2021-09-22 | — | — | EP | disclosed |
| EP-1836175-A2 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | MALLINCKRODT, INC. (US) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006071759-A2 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | MALLINCKRODT INC. (US) | 2006-07-06 | — | — | WO | disclosed |
| EP-0441976-B1 | 3,6-DIAMINO-2,5-PYRAZINEDICARBONITRILE AND PRODUCTION THEREOF | NIPPON SODA CO (JP) | 1994-11-17 | — | — | EP | disclosed |
| US-5317102-A | MANUFACTURED FROM THIO-SUBSTITUTED 2,3-DIAMINOACRYLONITRILE COMPOUNDS | NIPPON SODA CO., LTD. (JP) | 1994-05-31 | — | — | US | disclosed |
| US-5294711-A | 3,6-diamino-2,5-pyrazinedicarbonitrile | NIPPON SODA CO., LTD. (JP) | 1994-03-15 | — | — | US | disclosed |
| EP-0579835-A1 | WAVELENGTH CONVERSION MATERIAL FOR AGRICULTURE | NIPPON SODA CO., LTD. (JP) | 1994-01-26 | — | — | EP | disclosed |
| EP-0441976-A1 | 3,6-DIAMINO-2,5-PYRAZINEDICARBONITRILE AND PRODUCTION THEREOF | NIPPON SODA CO., LTD. (JP) | 1991-08-21 | — | — | EP | disclosed |
| US-4517186-A | BACTERICIDES, FUNGICIDES | MERCK & CO., INC. (US) | 1985-05-14 | — | — | US | disclosed |
| US-3948895-A | CURING AGENTS FOR EPOXY RESINS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1976-04-06 | — | — | US | disclosed |
| US-3948895-A | CURING AGENTS FOR EPOXY RESINS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1976-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11160880-B2 | Compositions and methods for assessing eye vasculature | LIPG, FLT4, FABP3 | USP8 1853/4885USP2 1405/4885USP5 1268/4885 |
| US-20220127237-A1 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | GLS, XDH, CYP4F12 | USP8 4740/4885USP2 4014/4885USP5 2243/4885 |
| US-20230132384-A9 | COMPOSITIONS AND METHODS FOR ASSESSING EYE VASCULATURE | LIPG, FLT4, FABP3 | USP8 1853/4885USP2 1405/4885USP5 1268/4885 |
| US-12303570-B2 | Compositions and methods for assessing eye vasculature | LIPG, FLT4, FABP3 | USP8 1853/4885USP2 1405/4885USP5 1268/4885 |
| US-20220016269-A1 | COMPOSITIONS AND METHODS FOR ASSESSING EYE VASCULATURE | LIPG, FLT4, FABP3 | USP8 1853/4885USP2 1405/4885USP5 1268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.